BiotechTube
Gateway Biotechnology

Gateway Biotechnology

St. Louis, United States· Est.
gtwbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200K

Overview

Gateway Biotechnology is a private, clinical-stage company pioneering novel treatments for hearing loss and tinnitus. Its lead program, GW-TT2, is an intranasal formulation of a repurposed drug targeting recent-onset tinnitus and is advancing under the FDA's 505(b)(2) regulatory pathway to reduce cost and risk. The company's scientific foundation is built on proprietary behavioral detection models and the expertise of its academic co-founders from Washington University in St. Louis and the University of Pittsburgh.

Hearing DisordersTinnitusSensorineural Hearing Loss

Technology Platform

Proprietary Sound-Based Avoidance Detection (SBAD) behavioral platform for tinnitus screening in rodents; multi-modal drug development strategy encompassing drug repurposing (intranasal delivery), new chemical entities, and gene therapy.

Funding History

1
Total raised:$200K
Grant$200K

Opportunities

The primary opportunity is addressing the massive, untreated market for tinnitus, where no FDA-approved drugs exist.
The 505(b)(2) regulatory pathway for its lead asset offers a faster, cheaper route to market with built-in de-risking.
Success could also pave the way for expansion into broader hearing loss and neurological conditions.

Risk Factors

Key risks include clinical trial failure for its repurposed drug in a new indication and route of administration, competition from other entrants in the growing field of hearing loss therapeutics, and the constant challenge of securing sufficient funding as a private, early-stage biotech company.

Competitive Landscape

The competitive landscape for tinnitus and hearing loss drugs is emerging but still nascent, with no approved pharmacotherapies. Gateway competes with other small biotechs (e.g., Otonomy, Decibel Therapeutics, Frequency Therapeutics have had mixed results) exploring various mechanisms. Its 505(b)(2) strategy with GW-TT2 could give it a potential first-mover advantage in the near term.

More companies in Small Molecule Drugs →More companies in United States →